LentiGlobin gene therapy for sickle cell on course for filing, says bluebirdIt has been an amazing year for patients with sickle cell disease (SCD) with two new drug approvals Share XLentiGlobin gene therapy for sickle cell on course for filing, says bluebirdhttps://pharmaphorum.com/news/lentiglobin-gene-therapy-for-sickle-cell-on-course-for-filing-says-bluebird/
Sanofi axes diabetes R&D, focuses on ‘transformative’ therapiesTake a look at Sanofi’s balance sheet and it’s obvious which way the wind is blowing – sales Share XSanofi axes diabetes R&D, focuses on ‘transformative’ therapieshttps://pharmaphorum.com/news/sanofi-axes-diabetes-and-cardio-rd-shifts-focus-on-transformative-therapies/
Nine for 2019: how did we do on our predictions, and what does this mean for 2020?Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead. At Share XNine for 2019: how did we do on our predictions, and what does this mean for 2020?https://pharmaphorum.com/views-and-analysis/nine-for-2019-2020/
DeepMatter will help AstraZeneca digitise discovery chemistryDigital technologies are permeating throughout pharma’s internal processes, and AstraZeneca has teamed up with DeepMatter to apply a Share XDeepMatter will help AstraZeneca digitise discovery chemistryhttps://pharmaphorum.com/news/deepmatter-will-help-astrazeneca-digitise-discovery-chemistry/
UCB posts more supportive data from Humira rival bimekizumabThere’s a whole gang of pharma companies queueing up to steal market share from AbbVie’s mega-blockbuster Humira, and Share XUCB posts more supportive data from Humira rival bimekizumabhttps://pharmaphorum.com/news/ucb-posts-more-supportive-data-from-humira-rival-bimekizumab/
Novartis pulls rival to Roche’s risdiplam in SMA, says market limitedWhile Roche’s oral risdiplam has been tipped by some analysts to be a big contender in the market Share XNovartis pulls rival to Roche’s risdiplam in SMA, says market limitedhttps://pharmaphorum.com/news/novartis-pulls-rival-to-roches-risdiplam-in-sma-says-market-limited/
The next decade of clinical trials innovationClinical trials have not fundamentally changed over the past 20 years, but there have been signs that practices Share XThe next decade of clinical trials innovationhttps://pharmaphorum.com/r-d/the-next-decade-of-clinical-trials-innovation/
Novartis says mid-stage pipeline is setting up strong growth spurtNovartis kicked off its R&D update in London this morning by pledging to bring at least 10 drugs Share XNovartis says mid-stage pipeline is setting up strong growth spurthttps://pharmaphorum.com/news/novartis-says-mid-stage-pipeline-is-setting-up-strong-growth-spurt/
Harnessing the digital transformation of the drug development pathwayWe have the evidence base to support the digital transformation of clinical trials – what we need now Share XHarnessing the digital transformation of the drug development pathwayhttps://pharmaphorum.com/views-analysis-digital/harnessing-the-digital-transformation-of-the-drug-development-pathway/
